Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2012

Open Access 01-12-2012 | Review

Surgical treatment of liver metastases of gastric cancer: state of the art

Authors: Fabrizio Romano, Mattia Garancini, Fabio Uggeri, Luca Degrate, Luca Nespoli, Luca Gianotti, Angelo Nespoli, Franco Uggeri

Published in: World Journal of Surgical Oncology | Issue 1/2012

Login to get access

Abstract

Background

The prognosis of patients with liver metastases from gastric cancer (LMGC) is dismal, and little is known about prognostic factors in these patients; so justification for surgical resection is still controversial. Furthermore the results of chemotherapy for these patients are disappointing. The purpose of this study was to review recent outcomes of hepatectomy for LMGC and to determine the suitable candidates for surgery, assessing the surgical results and clinicopathologic features. Moreover we compare these results with those obtained with alternative treatments.
Literature
1.
Jernal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics 2009. CA cancer J Clin. 2009, 59: 225-249. 10.3322/caac.20006.CrossRef
2.
Jl D, van de Velde CJ, Coit DG, Shah MA, Verheij M, Cats A: Treatment of resectable gastric cancer. Therap Adv Gastroenterol. 2012, 5: 49-69. 10.1177/1756283X11410771.CrossRef
3.
4.
Schlansky B, Sonnemberg A: Epidemiology of noncardia gastric adenocarcinoma in the United States. Am J Gastroenterol. 2011, 106: 1978-1985. 10.1038/ajg.2011.213.CrossRefPubMed
5.
Kemeny N: Management of liver metastases from colorectal cancer. Oncology. 2006, 20: 1161-1176.PubMed
6.
Minagawa M, Makuuchi M, Torzilli G, Takayama T, Kawasaki S, Kosuge T, Yamamoto J, Imamura H: Extension of the frontiers of surgical indication in the treatment of liver metastases from colorectal cancer. Ann Surg. 2000, 231: 487-499. 10.1097/00000658-200004000-00006.PubMedCentralCrossRefPubMed
7.
8.
Shirabe K, Wakiyama S, Gion T, Watanabe M, Miyazaki M, Yoshinaga K, Tokunaga M, Nagaie T: Hepatic resection for the treatment of liver metastases in gastric carcinoma: review of the literature. HPB. 2006, 8: 89-92. 10.1080/13651820500472168.PubMedCentralCrossRefPubMed
9.
Ambiru S, Miyazaki M, Ito H, Nakagawa K, Shimizu H, Yoshidome H, Shimizu Y, Nakajima N: Benefits and limits of hepatic resection for gastric metastases. Am J Surg. 2001, 181: 279-283. 10.1016/S0002-9610(01)00567-0.CrossRefPubMed
10.
Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999, 230: 309-318. 10.1097/00000658-199909000-00004.PubMedCentralCrossRefPubMed
11.
Kakeji Y, Morita M, Maehara Y: Strategies for treating liver metastases from gastric cancer. Surg Today. 2010, 40: 287-294. 10.1007/s00595-009-4152-0.CrossRefPubMed
12.
Ueda K, Iwahashi M, Nakamori M, Nakamura M, Naka T, Ishida K, Ojima T, Yamaue H: Analysis of the prognostic factors and evaluation of surgical treatment for synchronous liver metastases from gastric cancer. Langenbecks Arch Surg. 2009, 394: 647-653. 10.1007/s00423-008-0311-9.CrossRefPubMed
13.
Fujisaki S, Tomita R, Nezu T, Kimizuka K, Park E, Fukuzawa M: Prognostic studies on gastric cancer with concomitant liver metastases. Hepatogastroenterology. 2001, 48: 802-804.
14.
Linhares E, Monteiro M, Kesley R, Santos CE, Filho OS, Simoes JH: Major hepatectomy for isolated metastases from gastric adenocarcinoma. HPB. 2003, 5: 235-237. 10.1080/13651820310015815.PubMedCentralCrossRefPubMed
15.
Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M: Randomized comparison of fluorouracil epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with nonresectable gastric cancer. Br J Cancer. 1995, 71: 587-591. 10.1038/bjc.1995.114.PubMedCentralCrossRefPubMed
16.
Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenlam M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Marabotti C, Van Cutsem E, V-325 Study Group: Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastro-oesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007, 25: 3205-3209. 10.1200/JCO.2006.10.4968.CrossRefPubMed
17.
Yoshida M, Ohtsu A, Boku N, Miyata Y, Shirao K, Shimada Y, Hyodo I, Koizumi W, Kurihara M, Yoshida S, Yamamoto S: Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. Jpn J Clin Oncol. 2004, 34: 654-659. 10.1093/jjco/hyh120.CrossRefPubMed
18.
Cocconi G, Carlini P, Gamboni A, Gasperoni S, Rodinò C, Zironi S, Bisagni G, Porrozzi S, Cognetti F, Di Costanzo F, Canaletti R, Ruggeri EM, Camisa R, Pucci F: For the Italian Oncology Group for Clinical Research. Cisplatin, epirubicin, leucovorin and 5-fluorourail (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. Ann Oncol. 2003, 14: 1258-1263. 10.1093/annonc/mdg329.CrossRefPubMed
19.
Lee J, Kang WK, Kwon JM, Oh SY, Lee HR, Kim HJ, Park BB, Lim HY, Han MJ, Park JO, Park YS: Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma. Ann Oncol. 2007, 18: 88-92.CrossRefPubMed
20.
Cao W, Yang W, Lou G, Jilang J, Geng M, Xi W, Li H, Ma T, Jin Y: Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer. Anticancer Drugs. 2009, 20: 287-293. 10.1097/CAD.0b013e3283273509.CrossRefPubMed
21.
Liu J, Chen L: Current status and progress in gastric cancer with liver metastases. Chin Med J. 2011, 124: 445-456.PubMed
22.
Baba H, Okuyama T, Hiroyuki O, Anai H, Korenaga D, Maehara Y: Prognostic factors for noncurative gastric cancer: univariate and multivariate analysis. J Surg Oncol. 1992, 51: 104-108. 10.1002/jso.2930510208.CrossRefPubMed
23.
Imamura H, Matsuyama Y, Shimada R, Kubota M, Nakayama A, Kobayashi A, Kitamura H, Ikegami T, Miyagawa S, Kawasaki S: A study of factors influencing prognosis after resection of hepatic metastases from colorectal and gastric carcinoma. Am J Gastroenterol. 2001, 96: 3178-3184. 10.1111/j.1572-0241.2001.05278.x.CrossRefPubMed
24.
Thelen A, Jonas S, Benckert C, Lopez-Hänninen E, Neumann U, Rudolph B, Schumacher G, Neuhaus P: Liver resection for metastatic gastric cancer. Eur J Surg Oncol. 2008, 34: 1328-1334. 10.1016/j.ejso.2008.01.022.CrossRefPubMed
25.
Sakamoto Y, Ohyama S, Yamamoto J, Yamada K, Seki M, Ohta K, Kokudo N, Yamaguchi T, Muto T, Makuuchi M: Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients. Surgery. 2003, 133: 507-511. 10.1067/msy.2003.147.CrossRefPubMed
26.
Adam R, Chiche L, Aloia T, Elias D, Salmon R, Rivoire M, Jaeck D, Saric J, Le Treut YP, Belghiti J, Mantion G, Mentha G: For the Association Française de Chirurgie. Hepatic resection for noncolorectal nonendocrine liver metastases. Ann Surg. 2006, 244: 524-535.PubMedCentralCrossRefPubMed
27.
28.
Okano K, Maeba T, Ishimura K, Karasawa Y, Goda F, Wakabayashi H, Usuki H, Maeta H: Hepatic resection for metastatic tumors from gastric cancer. Ann Surg. 2002, 235: 86-91. 10.1097/00000658-200201000-00011.PubMedCentralCrossRefPubMed
29.
Roh HR, Suh KS, Lee HJ, Yang HK, Choe KJ, Lee KU: Outcome of hepatic resection for metastatic gastric cancer. Am Surg. 2005, 71: 95-99.PubMed
30.
Ochiai T, Sasako M, Mizuno S, Kinoshita T, Takayama T, Kosuge T, Yamazaki S, Maruyama K: Hepatic resection for metastatic tumours from gastric cancer: analysis of prognostic factors. Br J Surg. 1994, 81: 1175-1178. 10.1002/bjs.1800810832.CrossRefPubMed
31.
Saiura A, Umekita N, Inoue S, Maeshiro T, Miyamoto S, Matsui Y, Asakage M, Kitamura M: Clinicopathological features and outcome of hepatic resection for liver metastases from gastric cancer. Hepatogastroenterology. 2002, 49: 1062-1065.PubMed
32.
Japanese Gastric Cancer association: Japanese classification of gastric carcinoma. 2nd English edition. Gastric Cancer. 1998, 1: 10-24.CrossRefPubMed
33.
Zacherl J, Zacherl M, Scheuba C, Steininger R, Wenzl E, Muhlbacher F, Jakesz R, Langle F: Analysis of hepatic resection of metastases originating from gastric adenocarcinoma. J Gastrointest Surg. 2002, 6: 682-689. 10.1016/S1091-255X(01)00075-0.CrossRefPubMed
34.
Koga R, Yamamoto J, Ohyama S, Saiura A, Seki M, Yasuyuki S, Yamaguchi T: Liver resection for metastatic gastric cancer: experience with 42 patients including 8 long-term survivors. Jpn J Clin Oncol. 2007, 37: 836-842. 10.1093/jjco/hym113.CrossRefPubMed
35.
Kwak CM, Wu CW, Lo SS, Shen KH, Hsieh MC, Lui WY: Survival of gastric cancer with concomitant liver metastases. Hepatogastroenterology. 2004, 51: 1527-1530.
36.
Elias D, Cavalcanti de Albuquerque A, Eggenspieler P, Plaud B, Ducreux M, Spielmann M, Theodore C, Bonvalot S, Lasser P: Resection of liver metastases from a non-colorectal primary: indications and results based on 147 monocentric patients. J Am Coll Surg. 1998, 187: 487-493. 10.1016/S1072-7515(98)00225-7.CrossRefPubMed
37.
Cheon SH, Rha SY, Jeung HC, Im CK, Kim SH, Kim HR, Ahn JB, Roh JK, Noh SH, Chung HC: Survival benefit of combined curative resection of the stomach and liver in gastric cancer patients with liver metastases. Ann Oncol. 2008, 19: 1153-1158.CrossRef
38.
Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ, Kang WK, Suh CI, Bang YJ: A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer. 1993, 71: 3813-3818. 10.1002/1097-0142(19930615)71:12<3813::AID-CNCR2820711205>3.0.CO;2-5.CrossRefPubMed
39.
Bines SD, England G, Deziel DJ, Witt TR, Doolas A, Roseman DL: Synchronous, metachronous, and multiple hepatic resections of liver tumors originating from primary gastric tumors. Surgery. 1993, 114: 799-805.PubMed
40.
Morise Z, Sugioka A, Hoshimoto S, Kato T, Ikeda M, Uyama I, Horiguchi A, Miyakawa S: The role of hepatectomy for patients with liver metastases of gastric cancer. Hepatogastroenterology. 2008, 55: 1238-1241.PubMed
41.
Shirabe K, Shimada M, Matsumata T, Higashi H, Yakeishi Y, Wakiyama S, Ikeda Y, Ezaki T, Fukuzawa S, Takenaka K, Kishikawa K, Ikeda T, Taguchi K, Maehara Y, Sugimachi K: Analysis of the prognostic factors for liver metastases of gastric cancer after hepatic resection. A multi-insitutional study of the indications for resection. Hepatogastroenterology. 2003, 50: 1560-1563.PubMed
42.
Tsujimoto H, Ichikura T, Ono S, Sugasawa H, Hiraki S, Sakamoto N, Yaguchi Y, Hatsuse K, Yamamoyo J, Hase K: Outcomes for patients following hepatic resection of metastatic tumors from gastric cancer. Hepatol Int. 2010, 4: 406-413. 10.1007/s12072-009-9161-y.PubMedCentralCrossRefPubMed
43.
Miyazaki M, Itoh H, Nakagawa K, Ambiru S, Shimizu H, Togawa A, Shiobara M, Ohtsuka M, Sasada K, Shimizu Y, Yoshioka S, Nakajima N, Suwa T, Kimura F: Hepatic resection of liver metastases from gastric adenocarcinoma. Am J Surg. 1997, 92: 490-493.
44.
Sakamoto Y, Sano T, Shimada K, Esaki M, Saka M, Fukagawa T, Katai H, Kosuge T, Sasako M: Favorable indications for hepatectomy in patients with liver metastases from gastric cancer. J Surg Oncol. 2007, 95: 534-539. 10.1002/jso.20739.CrossRefPubMed
45.
Fujii K, Fujioka S, Kato K, Machici Y, Kutsuna Y, Ishikawa A, Takamizawa J, Ko K, Yoshida K, Nimura Y: Resection of liver metastases from gastric adenocarcinoma. Hepatogastroenterology. 2001, 48: 368-371.PubMed
46.
Romano F, Cesana G, Caprotti R, Bovo G, Uggeri F, Piacentini MG, Crippa S, Uggeri F: Pre-operative IL-2 immunotherapy enhances tumor inflitrating Lymphocytes (TILs) in gastric cancer patients. Hepatogastroenterology. 2006, 53: 634-638.PubMed
47.
Nomura T, Kamio Y, Takasu N, Moriya T, Takeshita A, Mizutani M, Hachiya O, Hirai I, Kimura W: Intrahepatic micrometastases around liver metastases from gastric cancer. J Hepatobiliary Pancreas Surg. 2009, 16: 493-501. 10.1007/s00534-009-0081-y.CrossRef
48.
Isono T, Miyazaki M, Udagawa I, Koshikawa H, Iimura M, Itoh H: The clinicopathological study of intrahepatic micrometastases in hepatic metastases carcinoma: comparison between hepatic metastases from gastric cancer and colorectal cancer. J Jpn Soc Cancer Ther. 1992, 27: 893-899.
49.
Makino H, Kunisaki C, Izumisawa Y, Tokuhisa M, Oshima T, Nagano Y, Fujii S, Kimura J, Takagawa R, Kosaka T, Ono HA, Akiyama H, Tanaka K, Endo I: Indication for hepatic resection in the treatment of liver metastasis from gastric cancer. Anticanc Res. 2010, 30: 2367-2376.
50.
Ueda K, Iwahashi M, Nakamori M, Nakamura M, Naka T, Ishida K, Ojima T, Yamaue H: Analysis of the prognostic factors and evaluation of sirgical treatment for synchronous liver metastases from gastric cancer. Langenbeks Arch Surg. 2009, 394: 647-653. 10.1007/s00423-008-0311-9.CrossRef
51.
Tiberio GAM, Coniglio A, Marchet A, Marrelli D, Giacopuzzi S, Baiocchi L, Roviello F, de Manzoni G, Nitti D, Giulini SM: Metachronous hepatic metastases from gastric carcinoma: a multicentric survey. EJSO. 2009, 35: 486-491. 10.1016/j.ejso.2008.12.017.CrossRefPubMed
52.
Hwang S-E, Yang D-H, Kim C-Y: Prognostic factors for survival in patients with hepatic recurrence after curative resection of gastric cancer. World J Surg. 2009, 33: 1468-1472. 10.1007/s00268-009-0034-2.CrossRefPubMed
53.
Yamakado K, Nakatsuka A, Takaki H, Mori Y, Tonouchi H, Kusunoki M, Kida H, Takeda K: Prospective study of arterial infusion chemotherapy followed by radiofrequency ablation for the treatment of liver metastasis of gastric cancer. J Vasc Interv Radiol. 2005, 16: 1747-1751. 10.1097/01.RVI.0000188738.84911.3B.CrossRefPubMed
54.
Kim HO, Hwang SI, Hong HP, Yoo CH: Radiofrequency ablation for metachronous hepatic metastases from gastric cancer. Surg Laparosc Endosc Percutan Tech. 2009, 19: 208-212. 10.1097/SLE.0b013e3181a033d7.CrossRefPubMed
Metadata
Title
Surgical treatment of liver metastases of gastric cancer: state of the art
Authors
Fabrizio Romano
Mattia Garancini
Fabio Uggeri
Luca Degrate
Luca Nespoli
Luca Gianotti
Angelo Nespoli
Franco Uggeri
Publication date
01-12-2012
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2012
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-10-157

Other articles of this Issue 1/2012

World Journal of Surgical Oncology 1/2012 Go to the issue

Research

The impact on clinical outcome of high prevalence of diabetes mellitus in Taiwanese patients with colorectal cancer

Research

Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway

Case report

Extragastrointestinal stromal tumor of the mesoappendix: CT findings and a review of the literature

Case report

Myoid hamartoma of the breast that proved difficult to diagnose: a case report

Case report

Traumatic neuroma in a patient with breast cancer after mastectomy: a case report and review of the literature

Research

Effect of L-arginine supplement on liver regeneration after partial hepatectomy in rats